Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma

Fineline Cube Mar 7, 2024

The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...

Company Drug

Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial

Fineline Cube Mar 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...

Company Deals

Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers

Fineline Cube Mar 7, 2024

Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....

Company Drug

Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals

Fineline Cube Mar 7, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company

Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters

Fineline Cube Mar 6, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...

Company Drug

Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer

Fineline Cube Mar 6, 2024

The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...

Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Company Deals Digital

ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine

Fineline Cube Mar 6, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...

Company

Lundbeck A/S Posts 8.2% YOY Revenue Growth in 2023 with Strong Performance Across Key Therapies

Fineline Cube Mar 6, 2024

Danish pharmaceutical company Lundbeck A/S (FRA: LDBB) has announced its financial results for 2023, highlighting...

Company Drug

Formosa Pharmaceuticals Secures FDA Nod for New Steroidal Eye Drug, Set to Launch via Eyenovia

Fineline Cube Mar 6, 2024

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has received approval from the US Food and Drug Administration...

Company Deals

MGI Tech Lands Eurofins Genomics Deal for T20 Ultra-High Throughput Sequencer in Europe

Fineline Cube Mar 6, 2024

MGI Tech (SHA: 688114), a China-based sequencing company, has announced a significant collaboration with Eurofins...

Company Drug

Bayer Posts 1.2% YOY Sales Decline in 2023 with Pharmaceuticals and Consumer Health Segment Updates

Fineline Cube Mar 6, 2024

Germany’s Bayer (ETR: BAYN) has released its financial results for 2023, marking a year of...

Company Drug

Novo Nordisk’s Ozempic Meets Phase III Endpoints in Type 2 Diabetes and Chronic Kidney Disease Study

Fineline Cube Mar 6, 2024

Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, has this week published results from a...

Company Drug

Sandoz Achieves FDA Milestone with Approval of First US Denosumab Biosimilars

Fineline Cube Mar 6, 2024

The US Food and Drug Administration (FDA) has granted Sandoz (SWX: SDZ), a Switzerland-based pharmaceutical...

Company Drug

Hybio Pharmaceutical Gets FDA Nod for Liraglutide Raw Materials with DMF Adequacy Letter

Fineline Cube Mar 6, 2024

Hybio Pharmaceutical Co., Ltd (SHE: 300199), a China-based pharmaceutical company, has announced that it has...

Company Drug

Shanghai RAAS Receives NMPA Approval to Initiate Clinical Trial for Hemophilia Preventive Treatment

Fineline Cube Mar 6, 2024

Shanghai RAAS (SHE: 002252), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Three Cancer Treatments Including a Novel ADC

Fineline Cube Mar 6, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, has received separate clinical trial approvals...

Policy / Regulatory

China’s Government Work Report Highlights Biomedicine Innovation and Healthcare Reforms

Fineline Cube Mar 5, 2024

Chinese Premier Li Qiang presented a concise Government Work Report at the Second Session of...

Company Drug

EMA Reviews Datopotamab Deruxtecan Filings from AstraZeneca and Daiichi Sankyo for Oncology Indications

Fineline Cube Mar 5, 2024

The European Medicines Agency (EMA) has accepted for review two oncology filings for the antibody-drug...

Posts pagination

1 … 385 386 387 … 658

Recent updates

  • Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication
  • Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A
  • WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion
  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Others

Allergan Aesthetics Secures Fourth NMPA Approval for Botox in China – Expanding Aesthetic Portfolio with Forehead Lines Indication

Others

Huahui Health Signs $1.9 Billion Global Licensing Deal with BeOne Medicines for Trispecific Antibody HH160 Targeting PD-1, CTLA-4, and VEGF-A

Company

WuXi AppTec Reports Record Q1 2026 Results with 28.8% Revenue Growth and RMB 59.77B Backlog – Chemistry Segment Leads Expansion

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.